Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells

Oxaliplatin is a platinum‐derived antitumor drug that is active against cisplatin‐resistant tumors and has lower overall toxicity than does cisplatin. DNA adduct formation is believed to mediate the cytotoxic activity of both compounds; however, the adducts may also be responsible for mutagenic and secondary tumorigenic activities. In this study, we have compared the mutagenicity of oxaliplatin and cisplatin in the Hprt gene of CHO‐K1 cells. Both drugs produced dose‐related increases in mutant frequency. For 1‐hr treatments, oxaliplatin was less mutagenic than cisplatin at equimolar doses, while similar mutant frequencies were induced at equitoxic doses. Sequencing of mutant Hprt genes indicated that the mutation spectra of both oxaliplatin and cisplatin were significantly different from the spontaneous mutation spectrum (P = 0.014 and P = 0.008, respectively). A significant difference was also observed between the spectra of oxaliplatin‐ and cisplatin‐induced mutations (P = 0.033). Although G:C→T:A transversion was the most common mutation produced by both compounds, oxaliplatin produced higher frequencies of A:T→T:A transversion than did cisplatin, most commonly at nucleotide 307, and higher frequencies of small deletions/insertions. Also, cisplatin induced tandem base‐pair substitutions, mainly at positions 135/136, and a higher frequency of G:C→A:T transition than did oxaliplatin. These results provide the first evidence that oxaliplatin is mutagenic and that the profiles of cisplatin‐ and oxaliplatin‐induced mutations display not only similarities but also distinctive features relating to the type and sequence‐context preference for mutation. Environ. Mol. Mutagen., 2005. © 2005 Wiley‐Liss, Inc.

[1]  Eric D. Scheeff,et al.  Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. , 1999, Molecular pharmacology.

[2]  B. Glickman,et al.  Sequence specificity of mutation induced by the anti-tumor drug cisplatin in the CHO aprt gene. , 1989, Carcinogenesis.

[3]  M. J. Pillaire,et al.  Mutagenesis in monkey cells of a vector containing a single d(GPG) cis- diamminedichloroplatinum(II) adduct placed on codon 13 of the human H- ras proto-oncogene , 1994, Nucleic Acids Res..

[4]  E. Raymond,et al.  Oxaliplatin: mechanism of action and antineoplastic activity. , 1998, Seminars in oncology.

[5]  P. Lohman,et al.  Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. , 1985, Biochemistry.

[6]  S. Lippard,et al.  Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II). , 1995, Nucleic acids research.

[7]  T. Kunkel,et al.  The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. , 1998, Cancer research.

[8]  E. Cvitkovic.  Ongoing and unsaid on oxaliplatin: the hope. , 1998, British Journal of Cancer.

[9]  C. Napier,et al.  Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. , 1998, Molecular pharmacology.

[10]  M. Giphart-Gassler,et al.  Heterozygous Aprt mouse model: Detection and study of a broad range of autosomal somatic mutations in vivo , 1999, Environmental and molecular mutagenesis.

[11]  S. Aebi,et al.  Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. , 1997, Cancer research.

[12]  R. Fuchs,et al.  Single d(ApG)/cis-diamminedichloroplatinum(II) adduct-induced mutagenesis in Escherichia coli. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Aardema,et al.  Characterization of p53 in Chinese hamster cell lines CHO-K1, CHO-WBL, and CHL: implications for genotoxicity testing. , 1999, Mutation research.

[14]  R. Rietbroek,et al.  In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. , 1996, Carcinogenesis.

[15]  B. A. Kunz,et al.  Analysis of mutations induced in the SUP4-o gene of Saccharomyces cerevisiae by cis-diammine dichloroplatinum(II). , 1990, Carcinogenesis.

[16]  H. Bleiberg.  Oxaliplatin (L-OHP): a new reality in colorectal cancer. , 1998, British Journal of Cancer.

[17]  M. Pillaire,et al.  In Vitro Bypass Replication of the Cisplatin-d(GpG) Lesion by Calf Thymus DNA Polymerase β and Human Immunodeficiency Virus Type I Reverse Transcriptase Is Highly Mutagenic* , 1996, The Journal of Biological Chemistry.

[18]  C. R. Valentine,et al.  Genomic DNA sequencing of mRNA splicing mutants in the hprt gene of chinese hamster ovary cells , 1995, Environmental and molecular mutagenesis.

[19]  I. M. Jones,et al.  Mapping the end points of large deletions affecting the hprt locus in human peripheral blood cells and cell lines. , 1995, Radiation research.

[20]  S. Chaney,et al.  The Role of DNA Polymerase η in Translesion Synthesis Past Platinum–DNA Adducts in Human Fibroblasts , 2004, Cancer Research.

[21]  D. Muzny,et al.  The Chinese hamster HPRT gene: restriction map, sequence analysis, and multiplex PCR deletion screen. , 1991, Genomics.

[22]  J. Thacker,et al.  Formation of large deletions by illegitimate recombination in the HPRT gene of primary human fibroblasts. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Schwartz,et al.  Dose-Dependent Changes in the Spectrum of Mutations Induced by Ionizing Radiation , 2000, Radiation research.

[24]  C. McCall,et al.  Frameshifts and deletions during in vitro translesion synthesis past Pt–DNA adducts by DNA polymerases β and η , 2002 .

[25]  R. Fuchs,et al.  Spectrum of cisplatin-induced mutations in Escherichia coli. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Marinus,et al.  MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA* , 2002, The Journal of Biological Chemistry.

[27]  I. Roninson,et al.  Identification of p53 genetic suppressor elements which confer resistance to cisplatin , 1997, Oncogene.

[28]  J. Essigmann,et al.  Mechanisms of resistance to cisplatin. , 2001, Mutation research.

[29]  W. T. Adams,et al.  Computer program for the analysis of mutational spectra: application to p53 mutations. , 1994, Carcinogenesis.

[30]  M. Marinus,et al.  Multiple pathways of recombination define cellular responses to cisplatin. , 2000, Chemistry & biology.

[31]  J. Miller,et al.  Mutagenicity, tumorigenicity, and electrophilic reactivity of the stereoisomeric platinum(II) complexes of 1,2-diaminocyclohexane. , 1981, Cancer research.

[32]  S. Ehrlich,et al.  RuvAB Acts at Arrested Replication Forks , 1998, Cell.

[33]  J. C. Jones,et al.  Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. , 1991, The Journal of biological chemistry.

[34]  E. Raymond,et al.  Oxaliplatin-induced damage of cellular DNA. , 2000, Molecular pharmacology.

[35]  M. J. Silva,et al.  Mutagenic activity of cisplatin in the lacZ plasmid‐based transgenic mouse model , 2002, Environmental and molecular mutagenesis.

[36]  P. van de Putte,et al.  Base-pair substitution hotspots in GAG and GCG nucleotide sequences in Escherichia coli K-12 induced by cis-diamminedichloroplatinum (II). , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[37]  E. Raymond,et al.  Oxaliplatin: a review of preclinical and clinical studies. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  T. Skopek,et al.  In vitro mutational specificity of cisplatin in the human hypoxanthine guanine phosphoribosyltransferase gene. , 1992, Cancer research.

[39]  P. Hall,et al.  Treatment-associated leukemia following testicular cancer. , 2000, Journal of the National Cancer Institute.

[40]  K. Paull,et al.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. , 1996, Biochemical pharmacology.

[41]  C. Macleod,et al.  In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. , 1997, Cancer research.

[42]  F. Zunino,et al.  Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. , 2003, Current cancer drug targets.

[43]  S. Lippard,et al.  Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum(II). , 1993, Biochemistry.

[44]  M. Meltz,et al.  Molecular nature of spontaneous mutations at the hypoxanthine‐guanine phosphoribosyltransferase (hprt) locus in chinese hamster ovary cells , 1995, Environmental and molecular mutagenesis.

[45]  M. Meuth,et al.  Deletion mapping of highly conserved transcribed sequence downstream fromAPRT locus , 1995, Somatic cell and molecular genetics.

[46]  E. Raymond,et al.  Activity of oxaliplatin against human tumor colony-forming units. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  D. Jenssen,et al.  Spectrum of spontaneously occurring mutations in the hprt gene of V79 Chinese hamster cells. , 1992, Journal of molecular biology.

[48]  F. Hanaoka,et al.  Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. , 2000, Biochemistry.

[49]  N. Berinstein,et al.  Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity , 1998, Oncogene.

[50]  J. Ward,et al.  Transplacental carcinogenesis by cisplatin in F344/NCr rats: promotion of kidney tumors by postnatal administration of sodium barbital. , 1995, Toxicology and Applied Pharmacology.

[51]  J. Wang,et al.  Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells , 1999, British Journal of Cancer.

[52]  P. Karran,et al.  Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. , 1997, Nucleic acids research.

[53]  S. Chaney.  The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review). , 1995, International journal of oncology.

[54]  P. Jordan,et al.  Molecular mechanisms involved in cisplatin cytotoxicity , 2000, Cellular and Molecular Life Sciences CMLS.

[55]  A. E. Kilburn,et al.  Recombination-dependent deletion formation in mammalian cells deficient in the nucleotide excision repair gene ERCC1. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. O'Connor,et al.  Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines , 1992, Molecular and cellular biology.

[57]  S. Faivre,et al.  DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. , 2003, Biochemical pharmacology.

[58]  Adams Wt,et al.  Statistical test for the comparison of samples from mutational spectra , 1987 .